首页> 美国卫生研究院文献>other >Neuroendocrine Tumor-Targeted Upconversion Nanoparticle-Based Micelles for Simultaneous NIR-Controlled Combination Chemotherapy and Photodynamic Therapy and Fluorescence Imaging
【2h】

Neuroendocrine Tumor-Targeted Upconversion Nanoparticle-Based Micelles for Simultaneous NIR-Controlled Combination Chemotherapy and Photodynamic Therapy and Fluorescence Imaging

机译:基于神经内分泌肿瘤靶向的上转换纳米粒子的胶束用于同时进行近红外控制的联合化疗和光动力疗法以及荧光成像

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Although neuroendocrine tumors (NETs) are slow growing, they are frequently metastatic at the time of discovery and no longer amenable to curative surgery, emphasizing the need for the development of other treatments. In this study, multifunctional upconversion nanoparticle (UCNP)-based theranostic micelles are developed for NET-targeted and near-infrared (NIR)-controlled combination chemotherapy and photodynamic therapy (PDT), and bioimaging. The theranostic micelle is formed by individual UCNP functionalized with light-sensitive amphiphilic block copolymers poly(4,5-dimethoxy-2-nitrobenzyl methacrylate)-polyethylene glycol (PNBMA-PEG) and Rose Bengal (RB) photosensitizers. A hydrophobic anticancer drug, AB3, is loaded into the micelles. The NIR-activated UCNPs emit multiple luminescence bands, including UV, 540 nm, and 650 nm. The UV peaks overlap with the absorption peak of photocleavable hydrophobic PNBMA segments, triggering a rapid drug release due to the NIR-induced hydrophobic-to-hydrophilic transition of the micelle core and thus enabling NIR-controlled chemotherapy. RB molecules are activated via luminescence resonance energy transfer to generate 1O2 for NIR-induced PDT. Meanwhile, the 650 nm emission allows for efficient fluorescence imaging. KE108, a true pansomatostatin nonapeptide, as an NET-targeting ligand, drastically increases the tumoral uptake of the micelles. Intravenously injected AB3-loaded UCNP-based micelles conjugated with RB and KE108—enabling NET-targeted combination chemotherapy and PDT—induce the best antitumor efficacy.
机译:尽管神经内分泌肿瘤(NETs)的生长缓慢,但发现时它们通常是转移性的,并且不再适合根治性手术,强调需要开发其他治疗方法。在这项研究中,基于多功能上转换纳米粒子(UCNP)的治疗胶束被开发用于NET靶向和近红外(NIR)控制的联合化疗和光动力疗法(PDT)以及生物成像。所述治疗胶束是由用光敏两亲嵌段共聚物聚(4,5-二甲氧基-2-甲基丙烯酸硝基苄基甲基酯)-聚乙二醇(PNBMA-PEG)和玫瑰红(RB)光敏剂官能化的单个UCNP形成的。将疏水性抗癌药物AB3装入胶束中。 NIR激活的UCNP发出多个发光带,包括UV,540 nm和650 nm。 UV峰与可光裂解的疏水性PNBMA片段的吸收峰重叠,由于NIR诱导的胶束核心疏水性至亲水性转变,触发了药物的快速释放,从而实现了NIR控制的化学疗法。 RB分子通过发光共振能量转移被激活,从而为NIR诱导的PDT生成 1 O2。同时,650 nm的发射允许高效的荧光成像。 KE108是一种真正的泛素他汀九肽,是一种靶向NET的配体,可显着增加胶束的肿瘤吸收。静脉注射AB3负载的UCNP基胶束与RB和KE108共轭,从而实现NET靶向联合化疗和PDT,可产生最佳的抗肿瘤功效。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号